ECX Stock Overview
A molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Epigenomics AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.65 |
| 52 Week High | €3.25 |
| 52 Week Low | €0.50 |
| Beta | 1.2 |
| 11 Month Change | -5.80% |
| 3 Month Change | 16.07% |
| 1 Year Change | -75.70% |
| 33 Year Change | -97.30% |
| 5 Year Change | -99.71% |
| Change since IPO | -99.89% |
Recent News & Updates
Recent updates
Shareholder Returns
| ECX | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.0% | 1.5% |
| 1Y | -75.7% | -15.4% | 12.6% |
Return vs Industry: ECX underperformed the German Biotechs industry which returned -15.4% over the past year.
Return vs Market: ECX underperformed the German Market which returned 12.6% over the past year.
Price Volatility
| ECX volatility | |
|---|---|
| ECX Average Weekly Movement | 15.3% |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: ECX's share price has been volatile over the past 3 months.
Volatility Over Time: ECX's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 6 | Noel Doheny | www.epigenomics.com |
Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company’s products also include Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA.
Epigenomics AG Fundamentals Summary
| ECX fundamental statistics | |
|---|---|
| Market cap | €568.85k |
| Earnings (TTM) | €2.96m |
| Revenue (TTM) | €136.23k |
0.2x
P/E Ratio4.2x
P/S RatioIs ECX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ECX income statement (TTM) | |
|---|---|
| Revenue | €136.23k |
| Cost of Revenue | €13.91k |
| Gross Profit | €122.32k |
| Other Expenses | -€2.84m |
| Earnings | €2.96m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.39 |
| Gross Margin | 89.79% |
| Net Profit Margin | 2,176.13% |
| Debt/Equity Ratio | -136.9% |
How did ECX perform over the long term?
See historical performance and comparison